VERO Biotech
  • Our Story
    • Overview
    • Board of Directors
    • Leadership Team
  • Solutions
    • Overview
    • Publications
  • Updates
    • Overview
    • In the News
  • Opportunities
  • Engagement
  • MEMBER LOGIN
  • Menu Menu
  • MEMBER LOGIN

In the News

You are here: Home1 / Updates2 / In the News
  • https://www.prnewswire.com/news-releases/vero-biotech-raises-30-million-to-accelerate-commercialization-of-its-innovative-tankless-inhaled-nitric-oxide-delivery-system-301718655.html

    VERO Biotech Raises $30 Million to Accelerate Commercialization of Its Innovative Tankless Inhaled Nitric Oxide Delivery System

    January 11, 2023

  • https://www.prnewswire.com/news-releases/vero-biotech-receives-fda-approval-of-its-third-generation-tankless-inhaled-nitric-oxide-delivery-system-301716118.html

    VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System

    January 9, 2023

  • https://www.prnewswire.com/news-releases/georgia-bio-awards-vero-biotech-the-2022-golden-helix-innovation-award-and-deal-of-the-year-award-301533840.html

    Georgia Bio Awards VERO Biotech the 2022 Golden Helix Innovation Award and Deal of the Year Award

    April 27, 2022

  • https://www.prnewswire.com/news-releases/vero-biotech-receives-funding-from-mvm-partners-to-accelerate-growth-301449098.html

    VERO Biotech Receives Funding from MVM Partners to Accelerate Growth

    December 21, 2021

  • http://digitaledition.rtmagazine.com/rtmagazi/diged/20210304/index.html

    New Publication Analyzes Interhospital Transport of Newborns Using VERO Biotech’s GENOSYL® Delivery System for the Delivery of Inhaled Nitric Oxide, Pg 20-24

    April 16, 2021

  • https://www.prnewswire.com/news-releases/georgia-bio-awards-2021-golden-helix-to-vero-biotech-for-best-deal-of-the-year-301261120.html

    Georgia Bio Awards 2021 Golden Helix to VERO Biotech for Best Deal of the Year

    April 2, 2021

  • https://respiratorytherapy.ca/pdf/RT-16-2-Spring-2021-R21.pdf

    New Publication Explores Hidden Costs of Tank-Based Inhaled Nitric Oxide Delivery Systems, Pg 51-54

    March 11, 2021

  • https://gabio.org

    VERO Biotech Awarded ‘Deal of the Year’ by Georgia Biotech

    March 4, 2021

  • https://pulmonaryhypertensionnews.com

    VERO Biotech Named Top Two Stories of 2020 by Pulmonary Hypertension News

    January 5, 2021

  • www.rtmagazine.com

    Inhaled Nitric Oxide: Past, Present, and Future

    June 25, 2020

  • www.respiratorytherapy.ca

    Respiratory Therapy Newsletter June

    June 2, 2020

  • https://www.medscape.com

    Inhaled Nitric Oxide Explored for COVID-19 Oxygenation

    May 14, 2020

  • https://www.webmd.com

    Inhaled Nitric Oxide Explored for COVID-19 Oxygenation

    May 14, 2020

  • https://www.respiratorytherapy.ca

    Case Report Details Success of Tankless Delivery System

    May 13, 2020

  • www.pulmonaryhypertensionnews.com

    At-home System of Inhaled Nitric Oxide Treats PAH Patient Infected With COVID-19

    May 11, 2020

  • www.ptcommunity.com

    Home Use of GENOSYL® Delivery System (DS) to Administer GENOSYL® (nitric oxide) gas for Inhalation for the Treatment of Pulmonary Hypertension Complicated by COVID-19 Infection Published in American Journal of Respiratory and Critical Care Medicine

    May 6, 2020

  • www.galusaustralis.com

    Global Inhaled Nitric Oxide (NO) Delivery Systems Market Research Report 2020 by COVID-19 Pandemic Economic Emergency Analysis, Industry Size, Future Growth Analysis by 2027

    May 01, 2020

  • www.empr.com

    Pipeline: Immunotherapies and Other Investigational Therapies for COVID-19

    April 30, 2020

  • www.ajc.com

    Georgia manufacturing shaken by virus, but some ramp up

    April 20, 2020

  • www.itresearchbrief.com

    Trends of Inhaled Nitric Oxide (NO) Delivery Systems Market Reviewed for 2020 with Industry Outlook to 2025

    April 20, 2020

  • www.medicaldevice-network.com

    VERO Biotech uses expanded access emergency for iNO delivery system

    March 27, 2020

  • www.biocentury.com

    COVID-19 roundup: biopharmas scramble to reassess clinical timelines; plus CEPI-Dynavax, and emergency approvals for Vero, Fosun

    March 27, 2020

  • www.finance.yahoo.com

    FDA Grants VERO Biotech Expanded Access Emergency Use for the Treatment of Patients with COVID-19, with the GENOSYL® DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide

    March 26, 2020

  • www.reuters.com

    BRIEF-FDA Grants Vero Biotech Expanded Access Emergency Use For Treatment Of Patients With COVID-19, With Genosyl Ds

    March 26, 2020

  • www.pulmonaryhypertensionnews.com

    COVID-19 Patient with PH Treated with iNO Via Genosyl, VERO Biotech Announces

    March 25, 2020

  • www.biocentury.com

    Regulatory roundup: BioMarin poised to have first U.S., EU hemophilia gene therapy; plus Allergan, Eisai, FibroGen, ViiV and Vero

    December 24, 2019

Contact Info

  • 387 Technology Circle NW
    Suite 125
    Atlanta, Georgia 30313

  • contactus@vero-biotech.com

  • PRODUCT INQUIRIES

    To report an adverse event, product questions or complaints, other safety-related information or technical support for a company product

  • 877-337-4118

  • support@vero-biotech.com

Quick Links

  • Our Story
  • Solutions
  • Publications
  • Opportunities
  • Prescribing Information
  • Engagement
  • Employees

Medical Inquiries

For medical inquiries, click on the Request Form below.

REQUEST FORM

  • Cigna Machine Readable Files

    This link leads to the machine-readable files that are made available in response to the federal Transparency in Coverage Rule and includes negotiated service rates and out-of- network allowed amounts between health plans and healthcare providers. The machine readable files are formatted to allow researchers, regulators, and application developers

  • Check our Privacy Policy
  • Facebook
  • LinkedIn
  • Instagram
© Copyright - VERO Biotech. All rights reserved. VERO Biotech and GENOSYL are registered trademarks of VERO Biotech Inc.
Indication & safety information Indication & safety info
EXPAND

More about Inhaled Nitric Oxide

Nitric oxide

A compound of one atom of nitrogen and one atom of oxygen—is a critically important molecule involved in many physiological and disease processes. This “startlingly simple” compound was dubbed Molecule of the Year in 1992 as it “unites neuroscience, physiology, and immunology, and revises scientists’ understanding of how cells communicate and defend themselves.”

Inhaled Nitric Oxide

Inhaled Nitric Oxide as a therapeutic agent is ideally suited to its purpose—to effect dilation of pulmonary vessels, thereby lowering pulmonary artery pressures. Importantly, delivered to the lung, and with a very short half-life of a few seconds in the blood, the effect of inhaled nitric oxide is selective for the pulmonary vasculature, rather than systemic, as with other types of vasodilators.

GENOSYL® (nitric oxide)

GENOSYL® (nitric oxide) gas for inhalation, relaxes vascular smooth muscle cells, which leads to vasodilation of the pulmonary capillaries. GENOSYL appears to increase the partial pressure of arterial oxygen (PaO2) by dilating pulmonary vessels in better ventilated areas of the lung, redistributing pulmonary blood flow away from lung regions with low ventilation/perfusion (V/Q) ratios toward regions with normal ratios.

Indication & Safety Information

GENOSYL® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

  • GENOSYL is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
  • Abrupt discontinuation of GENOSYL (nitric oxide) gas, for inhalation may lead to worsening oxygenation and increasing pulmonary artery pressure.
  • Methemoglobin, NO2 and PaO2 should be monitored during nitric oxide administration.
  • In patients with pre-existing left ventricular dysfunction, GENOSYL may increase pulmonary capillary wedge pressure leading to pulmonary edema. The most common adverse reaction is hypotension.
  • Nitric oxide donor compounds may have an additive effect with GENOSYL on the risk of developing methemoglobinemia.
  • Only validated ventilator systems or nasal cannulas should be used in conjunction with GENOSYL.
  • See package insert for additional Important Safety Information.